Gonadorelin is not an FDA-approved drug, but it may be lawfully prepared by a compounding pharmacy for an individual patient with a prescription from a licensed provider.
Status as of July 21, 2026
Gonadorelin is a synthetic decapeptide identical to natural gonadotropin-releasing hormone, and the published pharmacology is unusually clear on one point: its effect is set by the pattern of delivery, not the total amount. Supplied as a lyophilized powder that is reconstituted and injected, it stimulates pituitary LH and FSH output only when delivered in small intermittent pulses, while continuous exposure suppresses that same output. Gonadorelin is a prescription drug whose dose, interval, and route are defined by product labeling and set by a licensed prescriber, so the ranges described here document its pharmacology rather than a personal regimen.
Gonadorelin's biological effect is determined by the rhythm of delivery rather than dose alone, with intermittent pulses roughly every 60 to 120 minutes stimulating gonadotropin release and continuous exposure suppressing it.
Gonadorelin arrives as a sterile, white-to-off-white lyophilized powder, a dry form chosen because the peptide is far more stable than it is in solution, where hydrolysis steadily erodes potency. Preparation is not a preliminary to dosing but part of it: the diluent volume sets the concentration, and the concentration is what converts a prescribed microgram dose into an injected volume.
Gonadorelin is supplied as a lyophilized powder because the peptide hydrolyzes in solution, and the diluent volume selected at reconstitution sets the concentration that converts a prescribed microgram dose into an injected volume.
The pituitary gonadotroph is built to read a rhythm, not a steady level, which is why the delivery pattern decides whether gonadorelin turns the reproductive axis on or off. Intermittent pulses that imitate the hypothalamus sustain LH and FSH output; the identical molecule delivered continuously internalizes and desensitizes the GnRH receptor, so secretion is paradoxically suppressed.
| Delivery mode | Receptor effect | Gonadotropin output |
|---|---|---|
| Intermittent pulses (~60-120 min) | Receptor resets between bursts | LH and FSH sustained |
| Continuous or too-frequent | Receptor internalized and desensitized | LH and FSH suppressed |
The same gonadorelin molecule stimulates the pituitary when delivered in pulses roughly 60 to 120 minutes apart but suppresses it through receptor down-regulation when delivered continuously, so the timing interval is the mechanism rather than a fine-tuning detail.
Gonadorelin is given parenterally, and only two routes matter in practice: subcutaneous injection, the mainstay of pulsatile regimens, and intravenous injection, used mainly for diagnostic challenge testing and protocols needing a sharply defined pulse. Oral delivery is a non-starter, because digestive enzymes would destroy the peptide before absorption, which is why every practical route is an injection.
Gonadorelin is administered by subcutaneous injection for pulsatile therapeutic regimens, most often through a programmable infusion pump, and intravenously for diagnostic challenge testing, while oral administration is unusable because digestive enzymes destroy the peptide.
Reported dosing is a range anchored to purpose rather than a single number, because gonadorelin is used both to stimulate the axis over time and to provoke a one-time response. Therapeutic pulses are microgram-level and repeated on a natural-mimicking interval, while diagnostic use is a single measured challenge dose, and starting doses are frequently titrated against measured hormone levels rather than fixed at the outset.
In pulsatile therapeutic regimens gonadorelin is delivered as microgram-level pulses roughly every 60 to 120 minutes, whereas endocrine challenge testing uses a single measured dose followed by timed blood sampling of LH and FSH.
Purpose reshapes nearly every dosing variable, so a single drug looks quite different across its uses. A diagnostic aim gives one defined provocation dose and reads the response by timed blood draws; a therapeutic aim runs a sustained program of small pump-delivered pulses judged by hormone trends; a suppression aim inverts the logic and relies on continuous, long-acting exposure, which is why longer-acting analogs, not short-acting gonadorelin, usually fill that role.
| Objective | Dosing pattern | Measured endpoint |
|---|---|---|
| Diagnostic | Single challenge dose | Acute LH and FSH rise on timed sampling |
| Therapeutic stimulation | Repeated microgram pulses, pump-delivered | Hormone and clinical trends over weeks |
| Suppression | Continuous or long-acting exposure | Down-regulated axis, better suited to analogs |
A diagnostic goal fixes gonadorelin as a single challenge dose read by timed blood sampling, a therapeutic goal fixes it as repeating microgram pulses judged over weeks, and a suppression goal calls for continuous exposure better delivered by longer-acting GnRH analogs.
Gonadorelin sits firmly in prescription-only territory, and that status is itself a dosing constraint. Approved product labeling defines the indications, dose forms, and administration methods a prescriber works within, and because response is judged by measured hormone levels, dosing is expected where those measurements can be taken, which rules out casual or unmonitored use.
Gonadorelin is a prescription-only drug whose dose, form, and route are bounded by approved product labeling and a hormone-monitoring framework, so every legitimate dosing decision runs through a licensed prescriber rather than individual selection.
The failure modes cluster around pattern dependence, which makes timing errors uniquely consequential: a scheduling fault is a pharmacological fault when the biological signal is encoded in the rhythm rather than the amount. The signature hazard is that over-frequent or effectively continuous delivery flips intended stimulation into receptor down-regulation and paradoxical suppression of LH and FSH.
Because gonadorelin's signal is encoded in its rhythm, delivering pulses too frequently or continuously can down-regulate the GnRH receptor and paradoxically suppress LH and FSH, a failure mode a steady-dose drug would never present.
Storage and handling quietly determine whether a dose that is correct on paper is correct in the body, because a degraded peptide delivers less active drug than its label claims while looking unchanged. The stability picture splits sharply between the dry vial and the reconstituted solution.
Gonadorelin is stable in its lyophilized form under cool, light-protected storage but hydrolyzes once reconstituted, so a degraded solution can silently deliver a reduced dose that mimics a poor clinical response rather than a storage failure.
The specific dosing regimen is set by a licensed prescriber, a design feature of how gonadorelin is meant to be used rather than a disclaimer added at the end. Because response to a pattern-dependent hormone varies from person to person, the regimen is individualized and iterative, tuned to measured laboratory results rather than copied from a fixed template.
The dose, interval, and any changes to a gonadorelin regimen are set by a licensed prescriber who titrates against measured LH, FSH, and sex-hormone levels, because without those measurements there is no way to tell whether a chosen pattern is stimulating or suppressing the axis.
Educational use only. This article describes what the published scientific and clinical literature reports about Gonadorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
